US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Latigo Biotherapeutics Inc

22.64

+0.49002.21%

Post-market: 22.640.00000.00%19:30 EDT

Volume:164.84K

Turnover:3.80M

Market Cap:1.50B

PE:-13.51

High:23.79

Open:22.33

Low:22.33

Close:22.15

52wk High:25.93

52wk Low:17.22

Shares:66.30M

Float Shares:22.12M

Volume Ratio:0.75

T/O Rate:0.75%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6760

EPS(LYR):-129.2325

ROE:--

ROA:--

PB:-5.44

PE(LYR):-0.18

Loading ...

Overview Company News Filings

Latigo Biotherapeutics Q2 EPS $(27.59) Up From $(36.52) YoY, Sales $0.00, Same YoY

Benzinga Earnings

Latigo Biotherapeutics Posts Q2 FY26 Net Loss of $25.8 Million; G&A Expenses Rise 64.29% to $4.6 Million

Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

THOMSON REUTERS

Latigo Biotherapeutics Price Target Announced at $36.00/Share by Leerink Partners

Latigo Biotherapeutics initiated with a Buy at Jefferies

Guggenheim Initiates Latigo Biotherapeutics at Buy With $50 Price Target

MT Newswires Live

Latigo Biotherapeutics, Inc. : Leerink Partners Initiates Coverage with Outperform Rating; Target Price $36

THOMSON REUTERS

Latigo Biotherapeutics initiated with a Buy at Goldman Sachs

Latigo Biotherapeutics Files Initial Beneficial Ownership Statement for Sanofi

Foresite’s James Tananbaum Acquires 140,000 Latigo Biotherapeutics Shares for $2.52 Million

Latigo Biotherapeutics Completes IPO and Updates Governance

Latigo Biotherapeutics Adopts Amended and Restated Bylaws Tied to IPO Close

U.S. Stocks on the MOVE-Atlassian, Macerich, DoubleVerify

Non-Opioid Pain Drug Developer Soars Over 14% in Market Debut

Stock Track | Latigo Biotherapeutics Soars 16.67% in Nasdaq Debut After Upsized $345.6 Million IPO

Latigo Poised to Open Higher in NASDAQ Debut After Upsized $345.6 Million IPO

Latigo Biotherapeutics Ups IPO to 19.2 Million Shares

Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/LTGO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LTGO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LTGO\",,,,,undefined,":{"symbol":"LTGO","market":"US","secType":"STK","nameCN":"Latigo Biotherapeutics Inc","latestPrice":22.64,"timestamp":1789416000000,"preClose":22.15,"halted":0,"volume":164839,"hourTrading":{"tag":"盘后","latestPrice":22.64,"preClose":22.64,"latestTime":"19:30 EDT","volume":15,"amount":339.42,"timestamp":1789428600429,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.02212189616252831,"floatShares":22121291,"shares":66299347,"eps":-1.676,"marketStatus":"Not Yet Opened","change":0.49,"latestTime":"09-14 16:00:00 EDT","open":22.33,"high":23.79,"low":22.33,"amount":3802941.062121,"amplitude":0.065914,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.676,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":0,"adr":0,"listingDate":1786075200000,"exchange":"NASDAQ","adjPreClose":22.15,"postHourTrading":{"tag":"盘后","latestPrice":22.64,"preClose":22.64,"latestTime":"19:30 EDT","volume":15,"amount":339.42,"timestamp":1789428600429,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.748556},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LTGO\",,,,,undefined,":{"symbol":"LTGO","floatShares":22121291,"roa":"--","roe":"--","lyrEps":-129.23255,"volumeRatio":0.748556,"shares":66299347,"dividePrice":0,"high":23.79,"amplitude":0.065914,"preClose":22.15,"low":22.33,"week52Low":17.2201,"pbRate":"-5.44","week52High":25.93,"institutionHeld":0,"latestPrice":22.64,"eps":-1.676,"divideRate":0,"volume":164839,"delay":0,"ttmEps":-1.676,"open":22.33,"prevYearClose":18,"prevWeekClose":22.15,"prevMonthClose":22.02,"prevQuarterClose":18,"fiveDayClose":23.04,"twentyDayClose":19.49,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LTGO\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LTGO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LTGO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1788753600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LTGO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LTGO","date":"2026-09-11","current":-13.508353,"percent":0.25,"low":-14.220252,"twenty":-13.626145,"median":-12.513822,"eighty":-11.012163,"high":-10.257227,"avg":-12.24787,"sd":1.216522,"marketCap":1428087934},"quantilePoints":[{"date":"2026-08-07","current":-10.257227,"twenty":-10.257227,"median":-10.257227,"eighty":-10.257227,"marketCap":1140357438},{"date":"2026-08-14","current":-11.41033,"twenty":-11.020695,"median":-10.545739,"eighty":-10.380784,"marketCap":1268554881},{"date":"2026-08-21","current":-12.172536,"twenty":-11.41033,"median":-11.020695,"eighty":-10.534363,"marketCap":1353293842},{"date":"2026-08-28","current":-14.220252,"twenty":-12.724282,"median":-11.393266,"eighty":-10.557115,"marketCap":1580950750},{"date":"2026-09-04","current":-12.786851,"twenty":-12.786851,"median":-12.172536,"eighty":-10.978035,"marketCap":1421590914},{"date":"2026-09-11","current":-12.849682,"twenty":-13.626145,"median":-12.513822,"eighty":-11.012163,"marketCap":1428087934}],"updateTime":1789444874904},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LTGO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664804677","title":"Latigo Biotherapeutics Q2 EPS $(27.59) Up From $(36.52) YoY, Sales $0.00, Same YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2664804677","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664804677?lang=en_us&edition=fundamental","pubTime":"2026-09-04 05:04","pubTimestamp":1788469452,"startTime":"0","endTime":"0","summary":"Latigo Biotherapeutics (NASDAQ:LTGO) reported quarterly losses of $(27.59) per share. This is a 24.45 percent increase over losses of $(36.52) per share from the same period last year. The company reported $0.00 in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/09/61617346/latigo-biotherapeutics-q2-eps-27-59-36-52-yoy-sales-0-00-same-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Latigo Biotherapeutics Q2 EPS $(27.59) Up From $(36.52) YoY, Sales $0.00, Same YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664016848","title":"Latigo Biotherapeutics Posts Q2 FY26 Net Loss of $25.8 Million; G&A Expenses Rise 64.29% to $4.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2664016848","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664016848?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:17","pubTimestamp":1788466620,"startTime":"0","endTime":"0","summary":"Latigo Biotherapeutics posts Q2 FY26 net loss of $25.8 million; G&A expenses rise 64.29% to $4.6 millionLatigo posted a net loss of USD 25.8 million for Q2 2026, unchanged from Q2 2025.R&D expense sli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL9C61mB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTGO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664809283","title":"Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2664809283","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664809283?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:05","pubTimestamp":1788465902,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA4YKY7F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664432865","title":"Latigo Biotherapeutics Price Target Announced at $36.00/Share by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2664432865","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664432865?lang=en_us&edition=fundamental","pubTime":"2026-09-02 02:47","pubTimestamp":1788288420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LTGO/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664853864","title":"Latigo Biotherapeutics initiated with a Buy at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2664853864","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664853864?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:25","pubTimestamp":1788258349,"startTime":"0","endTime":"0","summary":"Jefferies initiated coverage of Latigo Biotherapeutics (LTGO) with a Buy rating and $50 price target The firm believes LTG-001 will show at least a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/latigo-biotherapeutics-initiated-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/latigo-biotherapeutics-initiated-with-a-buy-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LTGO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664398858","title":"Guggenheim Initiates Latigo Biotherapeutics at Buy With $50 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2664398858","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664398858?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:13","pubTimestamp":1788257583,"startTime":"0","endTime":"0","summary":"Guggenheim Initiates Latigo Biotherapeutics at Buy With $50 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664083071","title":"Latigo Biotherapeutics, Inc. : Leerink Partners Initiates Coverage with Outperform Rating; Target Price $36","url":"https://stock-news.laohu8.com/highlight/detail?id=2664083071","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664083071?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:05","pubTimestamp":1788257140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nFWN44T0C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883471","title":"Latigo Biotherapeutics initiated with a Buy at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883471?lang=en_us&edition=fundamental","pubTime":"2026-09-01 16:30","pubTimestamp":1788251407,"startTime":"0","endTime":"0","summary":"Goldman Sachs initiated coverage of Latigo Biotherapeutics (LTGO) with a Buy rating and $73 price target Latigo is clinical-stage biotechnology com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/latigo-biotherapeutics-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/latigo-biotherapeutics-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FHLC","LU0942090050.USD","LU2471134796.USD","LU2237443549.SGD","LU0251131958.USD","LU0106831901.USD","LU1868836914.USD","BK4504","LU0345770993.USD","LU1868837136.USD","SYNB","GSX","BK4127","FWD","LU1894683348.USD","IE0004086264.USD","LU1668664300.SGD","IE00B19Z3B42.SGD","BK4516","LU2896262040.SGD","LU2237438978.USD","LTGO","LU2237443895.HKD","LU2471134523.USD","LU2237443382.USD","IBB","BK4552","RSPH","BK4550","BBP","JDOC","IE0004091025.USD","IE0002270589.USD","IE00BSNM7G36.USD","LU1868836757.USD","LU2237443622.USD","AGNG","IE00BFXG1179.USD","LU1144417596.USD","DARP","BK4007","BBC","LNGR","BK4585","XT","LU0868494617.USD","LU0210536198.USD","LU1868836591.USD","LU0096364046.USD","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972487","title":"Latigo Biotherapeutics Files Initial Beneficial Ownership Statement for Sanofi","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972487","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972487?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:10","pubTimestamp":1786536651,"startTime":"0","endTime":"0","summary":"Latigo Biotherapeutics files initial beneficial ownership statement for SanofiSanofi filed a Form 3 disclosing 10% ownership in Latigo Biotherapeutics as of Aug. 6, 2026.Indirect beneficial ownership ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL74rSy8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658785950","title":"Foresite’s James Tananbaum Acquires 140,000 Latigo Biotherapeutics Shares for $2.52 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658785950","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658785950?lang=en_us&edition=fundamental","pubTime":"2026-08-11 08:00","pubTimestamp":1786406448,"startTime":"0","endTime":"0","summary":"Foresite’s James Tananbaum acquires 140,000 Latigo Biotherapeutics shares for $2.52 millionLatigo Biotherapeutics director James B. Tananbaum reported acquiring 3,562,984 shares of common stock throug","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL6456dW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Foresite’s James Tananbaum Acquires 140,000 Latigo Biotherapeutics Shares for $2.52 Million","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658957994","title":"Latigo Biotherapeutics Completes IPO and Updates Governance","url":"https://stock-news.laohu8.com/highlight/detail?id=2658957994","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658957994?lang=en_us&edition=fundamental","pubTime":"2026-08-11 06:20","pubTimestamp":1786400419,"startTime":"0","endTime":"0","summary":"An update from Latigo Biotherapeutics, Inc. ( ($LTGO) ) is now available. On August 10, 2026, Latigo Biotherapeutics, Inc. closed its initial publi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/latigo-biotherapeutics-completes-ipo-and-updates-governance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/latigo-biotherapeutics-completes-ipo-and-updates-governance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LTGO","KCE","IPOS","BK4127","FRHC","REDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658956232","title":"Latigo Biotherapeutics Adopts Amended and Restated Bylaws Tied to IPO Close","url":"https://stock-news.laohu8.com/highlight/detail?id=2658956232","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658956232?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:04","pubTimestamp":1786392261,"startTime":"0","endTime":"0","summary":"Latigo Biotherapeutics adopts amended and restated bylaws tied to IPO closeLatigo Biotherapeutics adopted amended and restated bylaws effective Aug. 10, 2026 in connection with its IPO closing.It also","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL3yN7JY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657401316","title":"U.S. Stocks on the MOVE-Atlassian, Macerich, DoubleVerify","url":"https://stock-news.laohu8.com/highlight/detail?id=2657401316","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657401316?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:39","pubTimestamp":1786120748,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Atlassian, Macerich, DoubleVerifyAug 7 (Reuters)-Wall Street's main indexes were on track for strong weekly gains on Friday after data showed the U.S. economy unexpectedly","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL6N4440XK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENPH","STX","NET","SEDG","MAC","VLO","DOCS","TTWO","PN","WEAV","BLSM","RWAY","ACMR","RUN","YJ","CVRX","TEAM","BETR","RMD","BLND","ASIX","MCHP","INVX","DV","RKT","STEP","VATE","WEN","XOM","FLR","MB","EXFY","NEM","VST","SG","UAA","CVX","TTD","MTW","REPL","ATGL","TRGP","LTGO","AU","FSLR","SEZL","BNL","COHR","XPOF","ABNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177328700","title":"Non-Opioid Pain Drug Developer Soars Over 14% in Market Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1177328700","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177328700?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:28","pubTimestamp":1786120091,"startTime":"0","endTime":"0","summary":"On Friday, Latigo Biotherapeutics (LTGO.US) made its public market debut, with shares surging more than 14% to $20.53 at the time of writing.The company is a developer of non-opioid pain medications...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185286978","title":"Stock Track | Latigo Biotherapeutics Soars 16.67% in Nasdaq Debut After Upsized $345.6 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1185286978","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185286978?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:42","pubTimestamp":1786117348,"startTime":"0","endTime":"0","summary":"Latigo Biotherapeutics (LTGO) surged 16.67% in intraday trading on Friday, marking a strong debut on the Nasdaq. The clinical-stage biopharmaceutical company's stock opened well above its initial...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641620","title":"Latigo Poised to Open Higher in NASDAQ Debut After Upsized $345.6 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641620","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641620?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:56","pubTimestamp":1786110990,"startTime":"0","endTime":"0","summary":"BUZZ-Latigo poised to open higher in Nasdaq debut after upsized $345.6 million IPO** Drug developer Latigo BiotherapeuticsLTGO.Oon track to open above offer price in Nasdaq debut after $345.6 million ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL6N4440OC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2471134879.HKD","BK4533","IE0034235188.USD","LU1894683264.USD","LU2471134523.USD","LU0742534661.SGD","LU0061475181.USD","LU1668664300.SGD","LU2750360997.AUD","LU2750360641.GBP","BK4588","IE00B19Z3581.USD","LU2471134796.USD","BK4504","IE0004086264.USD","BK4516","IE00BSNM7G36.USD","LU0096364046.USD","LTGO","LU2237443622.USD","BK4585","LU2237443549.SGD","LU0345770308.USD","BK4207","LU2237443382.USD","LU0942090050.USD","LU0345770993.USD","LU2471134952.CNY","LU2237438978.USD","LU0868494708.USD","BK4552","LU0106831901.USD","LU1894683348.USD","LU2237443465.HKD","IE0002270589.USD","MNSH","GSX","LU1868836914.USD","BK4127","LU2237443895.HKD","IE00BFXG1179.USD","IE0004091025.USD","LU0251142724.SGD","LU1791807156.HKD","LU1804176565.USD","LU2265009873.SGD","BK4550","LU1868836757.USD","LU0251131958.USD","LU0048573561.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657612453","title":"Latigo Biotherapeutics Ups IPO to 19.2 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2657612453","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657612453?lang=en_us&edition=fundamental","pubTime":"2026-08-07 18:17","pubTimestamp":1786097820,"startTime":"0","endTime":"0","summary":"Latigo Biotherapeutics increased its initial public offering to 19.2 million shares for $18 apiece.The clinical-stage biopharmaceutical company previously planned to sell 16 million shares at between ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","REDS","KCE","FRHC","BK4127","LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657693906","title":"Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2657693906","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657693906?lang=en_us&edition=fundamental","pubTime":"2026-08-07 08:03","pubTimestamp":1786060980,"startTime":"0","endTime":"0","summary":"THOUSAND OAKS, Calif., Aug.  06, 2026  (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medici","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/07/3340893/0/en/latigo-biotherapeutics-announces-pricing-of-upsized-345-6-million-initial-public-offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","LTGO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}